Talk
Oral Communications
Thu, Nov 19, 2026 · 1:05–2:35 PM EST Ballroom - 4th floor, Boston Marriott Copley Place
About this session
Oral communications: OC48 Dynamic changes in plasma biomarkers in patients treated with lecanemab: a longitudinal cohort study; OC49 ARO-MAPT, a Subcutaneously Delivered Shuttled siRNA Silencing Tau Production: Early Phase 1 Safety, Tolerability, and Pharmacodynamic Results in Healthy Volunteers; OC50 Lecanemab Treatment and α-Synuclein Co-Pathology in the Clarity AD CSF Substudy; OC51 Plasma eMTBR-tau as a biomarker for chronic traumatic encephalopathy tau tangle neuropathology; OC52 A proof of concept trial of MIB-626, a sirtuin-NAD+ activator, in mild Alzheimer's disease dementia; OC53 Distinct baseline topographies and short-interval spatiotemporal spread of [18F]MK-6240 tau PET in preclinical AD.
Speakers
-
Washington University School of Medicine
Chair
-
Brigham and Women's Hospital, Harvard Medical School
Chair